Ochre Bio appoints Elaine Sullivan as senior independent non-executive director
Ella Day | May 30, 2025 | Appointment | Research and Development | Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director
Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a wealth of experience in global pharma R&D and strategic leadership.
Sullivan previously served as vice president of global external R&D at Eli Lilly, where she managed a $100m portfolio, and as vice president at AstraZeneca, leading international R&D teams. Also, she has held non-executive roles at several biotechnology companies and brings a strong track record in global deal-making and novel drug development.
Commenting on the appointment, Sullivan said: “Ochre’s approach to liver disease therapeutics is highly innovative, particularly as chronic liver disease rates rise globally and treatment options remain limited. The integration of artificial Intelligence with human data to identify RNA therapies offers a compelling direction for the field.”
“I could not be more excited to welcome Elaine to the next phase of Ochre’s ambitions to progress successful RNA candidates to the clinic,” added Quin Wills, co-founder and chief scientific officer of Ochre Bio.
The company has also expanded its scientific leadership team. Julian Maller joins as head of in silico biology, bringing expertise in computational biology and genomics. Sarah Batey becomes head of portfolio development and scientific operations, with experience advancing drug candidates towards the clinic.
Ochre Bio is developing RNA-based therapies for chronic liver disease using a platform that combines machine learning, human tissue data and ex vivo liver models.
Ella Day
30/5/25
Related Content
University of Southern Denmark pairs with Argobio to launch next-generation RNA company Inverna Therapeutics
The launch of new RNA company Inverna Therapeutics was announced today. Inerva Therapeutics begins with …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
